On december 9, the European Medicines office reported that it had been a victim of a cyberattack. The announcement was of significant fear because EMA was considering was issuing authorizations for several COVID-19 vaccines. The next day, Pfizer announced that some documents it had submitted to EMA as part of that process had been involved in the cyberattack. Yesterday, the�Fareva group , a pharmaceutical manufacturer headquartered in Luxembourg, announced that it, too, has been the victim of a cyberattack. La Nouvelle R�publique reports (translation): In addition to the productions carried out for large pharmaceutical groups, such as Viagra, Fareva is preparing to package�an anti-Covid vaccine�created by a German laboratory CureVac. It sounds like production has amount to a abrasion halt and employees are placed on indefinite unemployment leave, but management is not issuing any statement confirming or denying any ransomware attack. Read more on La Nouvelle R�publique. h/t, @Chum1ng0